Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SYED ZAFAR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1811187909
CMS profile
218523
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$21,598.76

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $14,633.33 7
Honoraria $2,970.00 2
Travel and Lodging $2,000.00 1
Food and Beverage $1,896.43 95
Education $99.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SYED ZAFAR

NPI 1811187909 · CMS profile ID 218523

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811187909?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SYED ZAFAR, NPI 1811187909, CMS profile ID 218523. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811187909?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SYED ZAFAR, NPI 1811187909, CMS profile ID 218523. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811187909?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SYED ZAFAR, NPI 1811187909, CMS profile ID 218523, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–106 of 106 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1811187909?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $21,598.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–106 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $15.5101/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885662829 CMS
E.R. Squibb & Sons, L.L.C. $22.4801/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932538867 CMS
Genentech USA, Inc. $15.9501/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950804847 CMS
Merck Sharp & Dohme LLC $1,820.0001/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944728693 CMS
JAZZ PHARMACEUTICALS INC. $17.1501/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951337519 CMS
GENZYME CORPORATION $12.3901/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938992915 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,533.93 193
PY2020 $2,878.10 61
PY2021 $2,721.08 71
PY2022 $21,598.76 106
PY2023 $10,777.51 73
PY2024 $9,317.27 79
PY2025 $8,633.54 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $373,222.27 94
PY2024 Principal investigator $621,902.09 209
PY2023 Principal investigator $927,808.99 236
PY2022 Principal investigator $738,958.37 111
PY2021 Principal investigator $775,374.63 131
PY2020 Principal investigator $432,700.20 70
PY2019 Principal investigator $10,650.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $8,748.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650012
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175319185
Principal investigator 1 Janssen Research & Development, LLC $2,600.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175320806
Principal investigator 1 Genentech, Inc. $195.00 12/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650055
Principal investigator 1 Janssen Research & Development, LLC $562.50 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175321312
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322652
Principal investigator 1 Genentech, Inc. $533.00 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211650021
Principal investigator 1 Epizyme, Inc. $226.00 11/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283467
Principal investigator 1 Epizyme, Inc. $1,600.00 11/28/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283483
Principal investigator 1 AstraZeneca UK Limited $500.00 11/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185555167
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,994.64 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1235993783
Principal investigator 1 Epizyme, Inc. $2,131.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283463
Principal investigator 1 Epizyme, Inc. $2,131.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283465
Principal investigator 1 Epizyme, Inc. $1,600.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283469
Principal investigator 1 Epizyme, Inc. $1,600.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283471
Principal investigator 1 Epizyme, Inc. $1,800.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283473
Principal investigator 1 Epizyme, Inc. $2,131.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283475
Principal investigator 1 Epizyme, Inc. $2,131.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283477
Principal investigator 1 Epizyme, Inc. $1,800.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283485
Principal investigator 1 Epizyme, Inc. $2,131.00 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283487
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,166.00 11/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235993787
Principal investigator 1 Janssen Research & Development, LLC $1,787.50 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175323925
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328111
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328131
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328133
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322969
Principal investigator 1 Janssen Research & Development, LLC $512.50 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175323147
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325373
Principal investigator 1 SANOFI US SERVICES INC. $21,000.00 11/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst LLC
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant No dispute reported 06/30/2026 1226135943
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,905.67 11/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235993785
Principal investigator 1 Epizyme, Inc. $1,600.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283437
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283439
Principal investigator 1 Epizyme, Inc. $1,800.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283441
Principal investigator 1 Epizyme, Inc. $4,200.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283443
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283445
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283447
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283449
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283451
Principal investigator 1 Epizyme, Inc. $2,131.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283453
Principal investigator 1 Epizyme, Inc. $1,800.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283455
Principal investigator 1 Epizyme, Inc. $1,200.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283457
Principal investigator 1 Epizyme, Inc. $2,335.00 10/29/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283459
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328105
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328107
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328109
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328113
Principal investigator 1 BeOne Medicines USA, Inc. $44.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328115
Principal investigator 1 BeOne Medicines USA, Inc. $156.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328117
Principal investigator 1 BeOne Medicines USA, Inc. $44.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328119
Principal investigator 1 BeOne Medicines USA, Inc. $44.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328121
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328123
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328125
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328127
Principal investigator 1 BeOne Medicines USA, Inc. $156.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328129
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 10/07/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328135
Principal investigator 1 SANOFI US SERVICES INC. $1,370.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst LLC
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant No dispute reported 06/30/2026 1226136075
Principal investigator 1 SANOFI US SERVICES INC. $11,760.00 09/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst LLC
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant No dispute reported 06/30/2026 1226136079
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 09/09/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328099
Principal investigator 1 GlaxoSmithKline, LLC. $534.60 09/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150388
Principal investigator 1 GlaxoSmithKline, LLC. $1,567.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150392
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 08/20/2025 Non-covered Recipient Entity
Florida Cancer Specialists & Research Institute, LLC
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330103
Principal investigator 1 Celgene Corporation $12,390.67 08/13/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305510
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 08/12/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328101
Principal investigator 1 Genentech, Inc. $2,500.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211649837
Principal investigator 1 GlaxoSmithKline, LLC. $534.60 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150409
Principal investigator 1 SANOFI US SERVICES INC. $37.50 07/16/2025 Non-covered Recipient Entity
Sarah Cannon Research Inst LLC
A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade), Lenalidomide (Revlimid) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant No dispute reported 06/30/2026 1226136027
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 07/15/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328097
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 07/15/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190328103
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,200.00 07/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185555173
Principal investigator 1 Genentech, Inc. $3,473.75 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211649864
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175319310
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175320915
Principal investigator 1 GlaxoSmithKline, LLC. $1,006.00 06/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150396
Principal investigator 1 GlaxoSmithKline, LLC. $1,069.20 06/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150405
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 05/30/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190338951
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150401
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 05/05/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190338943
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,623.73 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185555165
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,029.58 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185555175
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 04/22/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190338947
Principal investigator 1 Mirati Therapeutics, Inc. $2,575.88 04/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530568
Principal investigator 1 GlaxoSmithKline, LLC. $1,069.20 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192150384
Principal investigator 1 BeiGene USA, Inc. $1,044.00 02/25/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190322624
Principal investigator 1 Celgene Corporation $2,083.00 02/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222307233
Principal investigator 1 GlaxoSmithKline, LLC. $534.60 02/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192098767
Principal investigator 1 GlaxoSmithKline, LLC. $534.60 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192098774
Principal investigator 1 Mirati Therapeutics, Inc. $3,723.00 02/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530564
Principal investigator 1 Celgene Corporation $51,266.08 01/17/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute Llc
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222307135
Principal investigator 1 AstraZeneca UK Limited $2,279.97 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185555169
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,391.00 01/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185555171
Principal investigator 1 Epizyme, Inc. $2,101.50 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283001
Principal investigator 1 Epizyme, Inc. $1,989.00 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283003
Principal investigator 1 Epizyme, Inc. $2,101.50 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283005
Principal investigator 1 Epizyme, Inc. $2,101.50 01/08/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184283007